About: Olivier Chinot

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Olivier Chinot Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

researcher

Attributes	Values
rdf:type	Item
description	forskare (sv) researcher (en) 연구원 (ko) 研究者 (ja) wetenschapper (nl) дослідник (uk) 研究者 (zh) հետազոտող (hy)
rdfs:label	O Chinot (es) O Chinot (nl) O Chinot (sl) O Chinot (ast) Olivier Chinot (en)
skos:prefLabel	O Chinot (es) O Chinot (nl) O Chinot (sl) O Chinot (ast) Olivier Chinot (en)
name	O Chinot (es) O Chinot (nl) O Chinot (sl) O Chinot (ast) Olivier Chinot (en)
given name	wds:Q56384070-9E31CB14-153B-4266-A58A-90FF31A437AA
given name	Olivier
instance of	wds:Q56384070-71F87DF3-8860-4288-B723-6CB787B98571
instance of	Homo sapiens
doctoral student	wds:Q56384070-37921EC6-9A15-450F-BCEA-CECAC50B1BF3
doctoral student	Emeline Tabouret
occupation	wds:Q56384070-629B0E58-B245-4436-95DF-415664220207
employer	wds:Q56384070-2A90D734-4C26-42FD-AD03-20C5BEC6B380 wds:Q56384070-A6000B16-23CB-4918-AE9F-386C0EA569D9
VIAF ID	wds:Q56384070-DBB2698D-AD7F-4A64-B10D-3ABF45F71DA2
GND ID	wds:Q56384070-efa0c7fa-7117-4d79-9bec-b8f0df4ad319
IdRef ID	wds:Q56384070-8A88946D-DB33-4D8A-93B0-E53576D4CF4E
educated at	wds:Q56384070-82E419C7-0798-45B3-9DE0-4651AFA5A434 wds:Q56384070-AF9F71DC-4F8B-4076-BCDB-93031E498D36 wds:Q56384070-C4228694-1C91-40B3-842F-B50747C2DED6 wds:Q56384070-EA5BB235-6F81-4568-837E-8C2E2B063CCF
WorldCat Identities ID (superseded)	wds:Q56384070-A7840038-0C6A-4860-9C8F-AD1DA034CA8B
VIAF ID	http://viaf.org/viaf/55145662620705031573
GND ID	https://d-nb.info/gnd/1084035049
IdRef ID	http://www.idref.fr/034791205/id
occupation	researcher
employer	University of Provence - Aix-Marseille I Assistance Publique-Hôpitaux de Marseille
VIAF ID	55145662620705031573
GND ID	1084035049
IdRef ID	034791205
educated at	University of Provence - Aix-Marseille I
WorldCat Identities ID (superseded)	viaf-55145662620705031573
ORCID iD	wds:Q56384070-0AA03F76-E308-481A-A9F6-6F55D3BE0E0D
ORCID iD	https://orcid.org/0000-0001-6317-9691
ORCID iD	0000-0001-6317-9691
ResearcherID	wds:Q56384070-956D8E35-322B-4F39-A417-CC0EC05591A1
ResearcherID	M-9196-2018
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q56384070
is author of	Chemotherapy for the treatment of oligodendroglial tumors Mitotic index, microvascular proliferation, and necrosis define 3 groups of 1p/19q codeleted anaplastic oligodendrogliomas associated with different genomic alterations Allelic loss of 9p21.3 is a prognostic factor in 1p/19q codeleted anaplastic gliomas EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis Recent developments in the molecular characterization and treatment of oligodendroglial tumors The role of Gamma Knife radiosurgery in the treatment of pineal parenchymal tumours [Role of adrenomedullin in glioblastomas growth]. Primary CNS lymphoma in patients younger than 60: can whole-brain radiotherapy be deferred? Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme. Bevacizumab, temozolomide, and radiotherapy for newly diagnosed glioblastoma: comprehensive safety results during and after first-line therapy Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF†. Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial Radiotherapy for glioblastoma in the elderly. Temozolomide Plus Bevacizumab in Elderly Patients with Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial (ATAG). Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma Tubulin isoforms identified in the brain by MALDI in-source decay Comparative assessment of 5 methods (methylation-specific polymerase chain reaction, MethyLight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to analyze O6-methylguanine-DNA-methyltranferase in a series of Prognostic value of cytosolic thymidine kinase activity as a marker of proliferation in breast cancer. Polysialic acid neural cell adhesion molecule (PSA-NCAM) is an adverse prognosis factor in glioblastoma, and regulates olig2 expression in glioma cell lines Response assessment criteria for glioblastoma: practical adaptation and implementation in clinical trials of antiangiogenic therapy. Prescription guidebook for temozolomide usage in brain tumors Multimodal MR imaging (diffusion, perfusion, and spectroscopy): is it possible to distinguish oligodendroglial tumor grade and 1p/19q codeletion in the pretherapeutic diagnosis? Histological and MR correlations in Gliomatosis cerebri Phase 1 dose-escalation study of the antiplacental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma. Recent trends in epidemiology of brain metastases: an overview. [Burkitt lymphoma of the cavernous sinus. Apropos of a case] Independent prognostic value of pre-treatment 18-FDG-PET in high-grade gliomas Clinical implications of quantitative real-time RT-PCR analysis of hTERT gene expression in human gliomas Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide MALDI imaging and in-source decay for top-down characterization of glioblastoma Links between private habits, psychological stress and brain cancer: a case-control pilot study in France. A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972. Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. Adult intracranial WHO grade II ependymomas: long-term outcome and prognostic factor analysis in a series of 114 patients Initial chemotherapy in gliomatosis cerebri. Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II study Chemotherapy and targeted treatments in glioblastomas

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 183 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software